Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Leadership from clinical stage artificial intelligence (AI)-powered drug discovery company Insilico Medicine ("Insilico") will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.

Related Keywords

Montreal ,Quebec ,Canada ,Boston ,Massachusetts ,United States ,Hong Kong ,Shanghai ,China ,San Diego ,California ,Suzhou ,Jiangsu ,Ashoka Madduri ,Jue Wang ,Michelle Chen ,Abu Dhabi ,Stacie Calad Thomson ,Mathieu Blanchette ,Christian Barrow ,Petrina Kamya ,Jimmy Yen Chu Lin ,Alex Zhavoronkov ,Martin Akerman ,Andrew Giessel ,Keith Mikule ,Michael Bembem ,Shell ,Mcgill University ,Business Development ,Johnson ,International Convention ,Head Of Business Development ,Astrazeneca ,Insilico Medicine ,Chief Business Officer Michelle Chen ,Vice President ,Insilico Medicine Taiwan ,Insilico Vice President ,Global Head ,Experimental Validation ,Drug Discovery ,Vice Chairperson ,Etai Jacob ,Nature Biotechnology ,